Temozolomide (GI/Carcinoid NET — Monotherapy) (Temodar) — Clinical FAQs

Question 1

What is Temozolomide (GI/Carcinoid NET — Monotherapy) FDA-approved to treat?

Accepted Answer

Temozolomide (GI/Carcinoid NET — Monotherapy) is FDA-approved for the following oncology indications: 1. Newly diagnosed glioblastoma multiforme (GBM) — concomitant with and following radiotherapy (Stupp protocol) 2. Refractory anaplastic astrocytoma 3. NOTE: Use in GI/carcinoid NETs is entirely off-label; temozolomide carries no FDA approval for neuroendocrine tumors of any type.

Question 2

How does Temozolomide (GI/Carcinoid NET — Monotherapy) work (mechanism of action)?

Accepted Answer

Oral imidazotetrazine prodrug that spontaneously converts to MTIC (methyltriazen-1-yl-imidazole-4-carboxamide) at physiological pH. MTIC methylates guanine at the O6 position, causing DNA mismatch, strand breaks, and apoptosis. Unlike streptozocin, temozolomide does not rely on GLUT2-mediated selective uptake into islet-derived cells — it distributes broadly to all tissues with good oral bioavailability and CNS penetration. The primary resistance mechanism is MGMT (O6-methylguanine-DNA methyltransferase), which directly repairs the O6-methylguanine adduct before it triggers apoptosis; MGMT promoter methylation silences the gene and predicts benefit. In GI/midgut carcinoid tumors, temozolomide acts as a non-selective cytotoxic alkylating agent — unlike streptozocin, it does not preferentially accumulate in enterochromaffin-derived tumor cells, so its activity profile in carcinoids reflects general alkylating agent efficacy rather than tumor-selective uptake.

Question 3

How is Temozolomide (GI/Carcinoid NET — Monotherapy) administered?

Accepted Answer

Temozolomide (GI/Carcinoid NET — Monotherapy) is administered Oral (PO). Standard 5-day schedule for NETs: Temozolomide 150–200 mg/m²/day orally once daily on days 1–5 of a 28-day cycle.

Question 4

What are the most common side effects of Temozolomide (GI/Carcinoid NET — Monotherapy)?

Accepted Answer

The most commonly reported side effects of Temozolomide (GI/Carcinoid NET — Monotherapy) (≥10% incidence) include: Nausea and vomiting (moderate emetic risk; 5-day schedule), Fatigue, Lymphopenia (universal; may be severe), Thrombocytopenia (nadir days 22–26), Neutropenia and others (9 total). Consult your oncologist for complete prescribing information.

Question 5

Does Temozolomide (GI/Carcinoid NET — Monotherapy) have a black box warning?

Accepted Answer

Yes. Temozolomide (GI/Carcinoid NET — Monotherapy) carries FDA black box warning(s) regarding: 1. Myelosuppression: severe thrombocytopenia and neutropenia; dose-limiting; monitor CBC on day 22 and day 28 of each cycle.

Question 6

Is Temozolomide (GI/Carcinoid NET — Monotherapy) safe during pregnancy?

Accepted Answer

Temozolomide (GI/Carcinoid NET — Monotherapy) pregnancy safety: Category D — Mutagenic, teratogenic, and carcinogenic in animal models. Effective contraception required during treatment and for at least 6 months after the last dose (both male and female patients). Breastfeeding must be discontinued during treatment.. Oncologists should review the complete prescribing information and discuss reproductive risks with patients before initiating therapy.

Temozolomide (GI/Carcinoid NET — Monotherapy) — Drug Monograph

Mechanism of Action

FDA Indications

Common Side Effects

Clinical Pearl

Related Therapies & Mechanisms